169 related articles for article (PubMed ID: 20953706)
1. Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population.
Chiorean MV; Pokhrel B; Adabala J; Helper DJ; Johnson CS; Juliar B
Dig Dis Sci; 2011 May; 56(5):1489-95. PubMed ID: 20953706
[TBL] [Abstract][Full Text] [Related]
2. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
[TBL] [Abstract][Full Text] [Related]
3. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low.
Farrell RJ; Ang Y; Kileen P; O'Briain DS; Kelleher D; Keeling PW; Weir DG
Gut; 2000 Oct; 47(4):514-9. PubMed ID: 10986211
[TBL] [Abstract][Full Text] [Related]
4. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe.
Lakatos PL; Lovasz BD; David G; Pandur T; Erdelyi Z; Mester G; Balogh M; Szipocs I; Molnar C; Komaromi E; Golovics PA; Vegh Z; Mandel M; Horvath A; Szathmari M; Kiss LS; Lakatos L
J Crohns Colitis; 2013 Jun; 7(5):385-91. PubMed ID: 22766526
[TBL] [Abstract][Full Text] [Related]
5. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort.
Ashworth LA; Billett A; Mitchell P; Nuti F; Siegel C; Bousvaros A
Inflamm Bowel Dis; 2012 May; 18(5):838-43. PubMed ID: 21887728
[TBL] [Abstract][Full Text] [Related]
6. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
7. Risk and clinical characteristics of lymphoma in Korean patients with inflammatory bowel diseases: a multicenter study.
Park SK; Ye BD; Lee C; Im JP; Kim YH; Kim SO; Byeon JS; Myung SJ; Yang SK; Kim JH
J Clin Gastroenterol; 2015 Feb; 49(2):e11-6. PubMed ID: 24705089
[TBL] [Abstract][Full Text] [Related]
8. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C
Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308
[TBL] [Abstract][Full Text] [Related]
9. Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics: A Quebec Claims Database Study.
Kopylov U; Vutcovici M; Kezouh A; Seidman E; Bitton A; Afif W
Inflamm Bowel Dis; 2015 Aug; 21(8):1847-53. PubMed ID: 25993693
[TBL] [Abstract][Full Text] [Related]
10. Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.
Khan N; Vallarino C; Lissoos T; Darr U; Luo M
Drugs Aging; 2017 Nov; 34(11):859-868. PubMed ID: 29170864
[TBL] [Abstract][Full Text] [Related]
11. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study.
Vos AC; Bakkal N; Minnee RC; Casparie MK; de Jong DJ; Dijkstra G; Stokkers P; van Bodegraven AA; Pierik M; van der Woude CJ; Oldenburg B; Hommes DW;
Inflamm Bowel Dis; 2011 Sep; 17(9):1837-45. PubMed ID: 21830262
[TBL] [Abstract][Full Text] [Related]
12. Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience.
Madanchi M; Zeitz J; Barthel C; Samaras P; Scharl S; Sulz MC; Biedermann L; Frei P; Vavricka SR; Rogler G; Scharl M
Digestion; 2016; 94(1):1-8. PubMed ID: 27318857
[TBL] [Abstract][Full Text] [Related]
13. Incidence, management, and course of cancer in patients with inflammatory bowel disease.
Algaba A; Guerra I; Marín-Jiménez I; Quintanilla E; López-Serrano P; García-Sánchez MC; Casis B; Taxonera C; Moral I; Chaparro M; Martín-Rodríguez D; Martín-Arranz MD; Manceñido N; Menchén L; López-Sanromán A; Castaño Á; Bermejo F
J Crohns Colitis; 2015 Apr; 9(4):326-33. PubMed ID: 25687203
[TBL] [Abstract][Full Text] [Related]
14. Risk of malignant lymphomas in patients with inflammatory bowel disease: a population-based cohort study.
Yu J; Refsum E; Wieszczy P; Helsingen LM; Perrin V; Högdén A; Løberg M; Blom J; Bretthauer M; Adami HO; Ye W; Kalager M
BMJ Open Gastroenterol; 2023 May; 10(1):. PubMed ID: 37142293
[TBL] [Abstract][Full Text] [Related]
15. Incidence and characteristics of the 2009 influenza (H1N1) infections in inflammatory bowel disease patients.
Naganuma M; Fujii T; Kunisaki R; Yoshimura N; Takazoe M; Takeuchi Y; Saito E; Nagahori M; Asakura K; Takebayashi T; Watanabe M
J Crohns Colitis; 2013 May; 7(4):308-13. PubMed ID: 22819592
[TBL] [Abstract][Full Text] [Related]
16. Lack of Increased Risk of Lymphoma with Thiopurine Therapy Regardless of Dose and Duration of Treatment in Japanese Patients with Inflammatory Bowel Diseases.
Kobayashi T; Udagawa E; Hibi T
Digestion; 2022; 103(2):169-173. PubMed ID: 34983046
[TBL] [Abstract][Full Text] [Related]
17. Risk of haematopoietic cancer in patients with inflammatory bowel disease.
Askling J; Brandt L; Lapidus A; Karlén P; Björkholm M; Löfberg R; Ekbom A
Gut; 2005 May; 54(5):617-22. PubMed ID: 15831904
[TBL] [Abstract][Full Text] [Related]
18. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.
Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA
Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975
[TBL] [Abstract][Full Text] [Related]
19. Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors-Results from the Swiss IBD Cohort Study.
Scharl S; Barthel C; Rossel JB; Biedermann L; Misselwitz B; Schoepfer AM; Straumann A; Vavricka SR; Rogler G; Scharl M; Greuter T
Am J Gastroenterol; 2019 Jan; 114(1):116-126. PubMed ID: 30333538
[TBL] [Abstract][Full Text] [Related]
20. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents.
Kwon JH; Farrell RJ
Crit Rev Oncol Hematol; 2005 Oct; 56(1):169-78. PubMed ID: 15979323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
